Tribune Therapeutics
Tribune Therapeutics is a biotechnology company developing disease-modifying therapies for fibrotic diseases. The company focuses on targeting the CCN family of proteins, which drive scar formation. Their lead program, TRX-44, is in development for treating fibrotic conditions like idiopathic pulmonary fibrosis (IPF).
Funding Round: Series A
Funding Amount: €23M
Date: 26-Mar-2025
Investors: LifeArc Ventures, Novo Holdings, HealthCap, Innovestor's Life Science Fund, Inven2, Industrifonden, Investinor
Markets: Biotech, Therapeutics, Pharmaceuticals
HQ: Copenhagen, Denmark
Founded: 2020
Website: https://www.tribunetx.com/
LinkedIn: https://www.linkedin.com/company/tribune-therapeutics/
Crunchbase: https://www.crunchbase.com/organization/tribune-therapeutics
Leave a Comment
Comments
No comments yet.